Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market
Go back to Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market| eLandia International, Inc. (NYSE: ELAN) | Delayed: 25.23 +0.23 (0.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.00 | 52 Week High | $0.65 | |||
| Open | $25.11 | 52 Week Low | $0.03 | |||
| Day High | $25.29 | P/E | N/A | |||
| Day Low | $24.76 | EPS | $-0.60 | |||
| Volume | 2,636,760 | |||||
